UroGen Pharma: There Is Some Potential Here [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Looking for more investing ideas like this one? Get them exclusively at The Biotech Forum. Learn More » Md Saiful Islam Khan/iStock via Getty Images Today, we put UroGen Pharma Ltd. ( NASDAQ: URGN in the spotlight for the very first time here on Seeking Alpha. The company's focus is on developing therapies for urothelial and specialty cancers. UroGen has one product on the market already and has other efforts within its pipeline. Our initial analysis around UroGen Pharma follows below. Seeking Alpha
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now [Yahoo! Finance]Yahoo! Finance
- UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041Business Wire
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector [Seeking Alpha]Seeking Alpha
- UroGen Pharma to Present at Upcoming Investor ConferencesBusiness Wire
URGN
Earnings
- 8/13/24 - Miss
URGN
Sec Filings
- 9/24/24 - Form 8-K
- 9/13/24 - Form 8-K
- 9/12/24 - Form 4
- URGN's page on the SEC website